GT200500049A - DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS - Google Patents

DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS

Info

Publication number
GT200500049A
GT200500049A GT200500049A GT200500049A GT200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A
Authority
GT
Guatemala
Prior art keywords
naftiridine
derivatives
diabetes
related disorders
treat diabetes
Prior art date
Application number
GT200500049A
Other languages
Spanish (es)
Inventor
Rainer Heurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500049A publication Critical patent/GT200500049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5,R6,R7, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD PARA TRATAR O PREVENIR PATOLOGIAS TALES COMO LA DIABETES DE TIPO 1 O TIPO 2, DIABETES JUVENIL DE INICIO EN LA MADUREZ, DIABETES AUTOINMUNE DEL ADULTO PRINCIPALMENTE. T2005THIS INVENTION CONCERNS COMPOUNDS OF GENERAL FORMULA I IN WHICH R1, R2, R3, R4, R5, R6, R7, ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. THESE COMPOUNDS ARE USEFUL TO TREAT OR PREVENT PATHOLOGIES SUCH AS DIABETES OF TYPE 1 OR TYPE 2, YOUTH STARTING DIABETES IN MATURITY, DIABETES AUTOINMUNE OF THE ADULT MAINLY. T2005

GT200500049A 2004-03-12 2005-03-11 DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS GT200500049A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55297104P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
GT200500049A true GT200500049A (en) 2005-10-24

Family

ID=35056657

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500049A GT200500049A (en) 2004-03-12 2005-03-11 DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS

Country Status (6)

Country Link
AR (1) AR048088A1 (en)
GT (1) GT200500049A (en)
PE (1) PE20060332A1 (en)
TW (1) TW200538124A (en)
UY (1) UY28805A1 (en)
WO (1) WO2005091857A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
JP5677425B2 (en) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Pyrimidinone as a PI3K inhibitor
FR2952934B1 (en) * 2009-11-23 2012-06-22 Sanofi Aventis PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
KR101898610B1 (en) 2010-08-31 2018-09-14 서울대학교산학협력단 Fetal reprogramming of PPARδ agonists
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CA2839395A1 (en) 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
KR102507287B1 (en) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Heterocyclylamines as pi3k inhibitors
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
PE20180129A1 (en) 2015-02-27 2018-01-18 Incyte Corp PI3K INHIBITOR SALTS AND PREPARATION PROCESSES
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
JOP20180097B1 (en) * 2018-10-22 2023-03-28 Univ Of Jordan 1,8-naphthyridine gluosamine derivatives,their use in the treatment of microbial infections,and amethod for preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL51092A0 (en) * 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Also Published As

Publication number Publication date
AR048088A1 (en) 2006-03-29
UY28805A1 (en) 2005-09-30
TW200538124A (en) 2005-12-01
PE20060332A1 (en) 2006-06-01
WO2005091857A2 (en) 2005-10-06
WO2005091857A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
GT200500049A (en) DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS
CL2008000212A1 (en) COMPOUNDS DERIVED FROM PHENOTIAZINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT DIABETES, REDUCE THE LEVELS OF GLUCEMIA, ADDICTION TO NICOTINE, ADDICTION TO ALCOHOL, DISORDERS OF THE CENTRAL NERVOUS SYSTEM, BETWEEN
GT200600197A (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN QUINASA INHIBITORS
ECSP088283A (en) PIRIDINE COMPOUNDS 5- (PHENYLISOXAZOLILETOXI) -TRIAZOL- 3-ILO SUBSTITUTED FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
GT200600167A (en) DERIVATIVES OF DIHYDROBENZOFURAN AND USES OF THE SAME
BRPI0411528A (en) use of isomalt as prebiotic
UY31239A1 (en) SULFONAMIDS AS TRPM8 MODULATORS
EA200602243A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
DOP2009000134A (en) BICYCLIC COMPOUNDS AND ITS USE AS ANTI-DIABETICS
UY30314A1 (en) BENZONITRILE DERIVATIVES REPLACED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, USE AND PROCEDURE FOR MANUFACTURING
GT200500208A (en) USEFUL INDAZOLS TO TREAT CARDIOVASCULAR DISEASES
ECSP055964A (en) HETEROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6
NO20090029L (en) Pyrrolopyrimidines for Pharmaceutical Formulations
EA200602242A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
CR10401A (en) INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE 1
BRPI0511907A (en) new disubstituted phenylpiperidine / piperizine derivatives as modulators of dopamine neurotransmission
GT200300219A (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MY143241A (en) 3, 5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
UY32312A (en) 4-AZETIDINIL-1-HETEROARIL-CICLOHEXANOL ANTAGONISTS OF CCR2
CR10682A (en) TIAZOL PIRAZOLOPIRIMIDINE COMPOUNDS
GT200600017A (en) 4-SUBSTITUTED PHENYLTHETHYROCHINOLINES, PROCESS FOR PREPARATION, USE AS A MEDICINAL PRODUCT AND MEDICINAL PRODUCT
SE0401465D0 (en) New substituted piperdines as modulators of dopamine neurotransmission
ECSP109961A (en) DERIVATIVES OF INDOL-2-ONA DISSTITUTED IN 3, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CO6470792A2 (en) ARILSULFONAMIDE 2.5-DISPOSED CCR3 ANTAGONISTS
CR9733A (en) DERIVATIVES OF AZINIL-3-SULFONYLINDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6